In summary, this study revealed that pediatric patients with CDKN2A/B deletion generally present with the following clinical characteristics: a greater proportion of T-ALL patients, a higher median white blood cell count at diagnosis, and a greater proportion in the age >10 years. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.